Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Brune, Karl D ^a   Leneghan, Darren B ^b   Brian, Iona J ^b   Ishizuka, Andrew S ^b   Bachmann, Martin F ^b,c   Draper, Simon J ^b   Biswas, Sumi ^b   Howarth, Mark ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; PEPTIDE; VIRUS ANTIGEN; VIRUS LIKE PARTICLE VACCINE;

BACTERIOPHAGE; ESCHERICHIA COLI; GENETICS; HUMAN; IMMUNOLOGY; VACCINATION; VIRUS CAPSID;

ANTIGENS, VIRAL; BACTERIOPHAGES; CAPSID; CAPSID PROTEINS; ESCHERICHIA COLI; HUMANS; PEPTIDES; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84955474149     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19234     Document Type: Article

References (72)

1. Sapsford, K. E. et al. Functionalizing Nanoparticles with Biological Molecules: Developing Chemistries that Facilitate Nanotechnology. Chem. Rev. 113, 1904-2074 (2013).
2. De Gregorio, E. & Rappuoli, R. From empiricism to rational design: A personal perspective of the evolution of vaccine development. Nat. Rev. Immunol. 14, 505-514 (2014).
3. Draper, S. J. & Heeney, J. L. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol. 8, 62-73 (2010).
4. Marston, H. D., Folkers, G. K., Morens, D. M. & Fauci, A. S. Emerging Viral Diseases: Confronting Threats with New Technologies. Sci. Transl. Med. 6, 1-6 (2014).
5. Smith, D. M., Simon, J. K. & Baker Jr, J. R. Applications of nanotechnology for immunology. Nat. Rev. Immunol. 13, 592-605 (2013).
6. Bachmann, M. F. & Jennings, G. T. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787-796 (2010).
7. Hua, Z. & Hou, B. TLR signaling in B-cell development and activation. Cell. Mol. Immunol. 10, 103-106 (2013).
8. Zabel, F., Kündig, T. M. & Bachmann, M. F. Virus-induced humoral immunity: on how B cell responses are initiated. Curr. Opin. Virol. 3, 357-362 (2013).
9. Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J. T. & Alves, P. M. Virus-like particles in vaccine development. Expert Rev. Vaccines 9, 1149-1176 (2010).
10. Jain, N. K. et al. Formulation and stabilization of recombinant protein based virus-like particle vaccines. Adv. Drug Deliv. Rev. 93, 42-55 (2014).
11. Schiller, J. T. & Müller, M. Next generation prophylactic human papillomavirus vaccines. Lancet Oncol. 16, e217-e225 (2015).
12. Bachmann, M. F. & Whitehead, P. Active immunotherapy for chronic diseases. Vaccine 31, 1777-1784 (2013).
13. Ratsimandresy, R. A., Rappaport, J. & Zagury, J.-F. Anti-cytokine therapeutics: history and update. Curr. Pharm. Des. 15, 1998-2025 (2009).
14. Patel, J. M. et al. Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity. Biotechnol. Bioeng. 112, 1102-1110 (2015).
15. Smith, M. T., Hawes, A. K. & Bundy, B. C. Reengineering viruses and virus-like particles through chemical functionalization strategies. Curr. Opin. Biotechnol. 24, 620-626 (2013).
16. Mateu, M. G. Virus engineering: functionalization and stabilization. Protein Eng. Des. Sel. 24, 53-63 (2011).
17. Walker, A., Skamel, C. & Nassal, M. SplitCore: An exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structure. Sci. Rep. 1, 5 (2011).
18. Mascola, J. R. & Montefiori, D. C. The Role of Antibodies in HIV Vaccines. Annu. Rev. Immunol. 28, 413-444 (2010).
19. Sletten, E. M. & Bertozzi, C. R. Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality. Angew. Chem. Int. Ed. 48, 6974-6998 (2009).
20. Jegerlehner, A. et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20, 3104-3112 (2002).
21. Pattenden, L. K., Middelberg, A. P. J., Niebert, M. & Lipin, D. I. Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol. 23, 523-529 (2005).
22. Anelli, T. et al. Thiol-mediated protein retention in the endoplasmic reticulum: The role of ERp44. EMBO J. 22, 5015-5022 (2003).
23. Baneyx, F. & Mujacic, M. Recombinant protein folding and misfolding in Escherichia coli. Nat. Biotechnol. 22, 1399-1408 (2004).
24. Koho, T. et al. His-tagged norovirus-like particles: A versatile platform for cellular delivery and surface display. Eur. J. Pharm. Biopharm. 96, 22-31 (2015).
25. Tong, G. J., Hsiao, S. C., Carrico, Z. M. & Francis, M. B. Viral Capsid DNA Aptamer Conjugates as Multivalent Cell-Targeting Vehicles. J. Am. Chem. Soc. 131, 11174-11178 (2009).
26. Strable, E. & Finn, M. G. In Viruses and Nanotechnology (eds. Manchester, M. & Steinmetz, N. F.) 327, 1-21 (Springer Berlin Heidelberg, 2009).
27. Patel, K. G. & Swartz, J. R. Surface Functionalization of Virus-Like Particles by Direct Conjugation Using Azide? Alkyne Click Chemistry. Bioconjug. Chem. 22, 376-387 (2011).
28. Sasmal, P. K. et al. Catalytic azide reduction in biological environments. Chembiochem 13, 1116-1120 (2012).
29. van den Bosch, S. M. et al. Evaluation of strained alkynes for Cu-free click reaction in live mice. Nucl. Med. Biol. 40, 415-423 (2013).
30. Versteegen, R. M., Rossin, R., ten Hoeve, W., Janssen, H. M. & Robillard, M. S. Click to Release: Instantaneous Doxorubicin Elimination upon Tetrazine Ligation. Angew. Chem. Int. Ed. 52, 14112-14116 (2013).
31. Aerni, H. R., Shifman, M. A., Rogulina, S., O'Donoghue, P. & Rinehart, J. Revealing the amino acid composition of proteins within an expanded genetic code. Nucleic Acids Res. 43, e8 (2015).
32. Veggiani, G., Zakeri, B. & Howarth, M. Superglue from bacteria: unbreakable bridges for protein nanotechnology. Trends Biotechnol. 32, 506-512 (2014).
33. Zakeri, B. et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc. Natl. Acad. Sci. 109, E690-E697 (2012).
34. Li, L., Fierer, J. O., Rapoport, T. A. & Howarth, M. Structural analysis and optimization of the covalent association between SpyCatcher and a peptide Tag. J. Mol. Biol. 426, 309-317 (2014).
35. Veggiani, G. & de Marco, A. Improved quantitative and qualitative production of single-domain intrabodies mediated by the coexpression of Erv1p sulfhydryl oxidase. Protein Expr. Purif. 79, 111-114 (2011).
36. Klovins, J., Overbeek, G. P., van den Worm, S. H. E. van den, Ackermann, H.-W. & van Duin, J. Nucleotide sequence of a ssRNA phage from Acinetobacter: kinship to coliphages. J. Gen. Virol. 83, 1523-1533 (2002).
37. Tissot, A. C. et al. Versatile virus-like particle carrier for epitope based vaccines. PloS One 5, e9809 (2010).
38. van den Worm, S. H. E., Koning, R. I., Warmenhoven, H. J., Koerten, H. K. & van Duin, J. Cryo electron microscopy reconstructions of the Leviviridae unveil the densest icosahedral RNA packing possible. J. Mol. Biol. 363, 858-865 (2006).
39. Spohn, G. et al. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol. J. 7, 146 (2010).
40. Lau, C. K. Y. et al. Structural conservation despite huge sequence diversity allows EPCR binding by the PfEMP1 family implicated in severe childhood malaria. Cell Host Microbe 17, 118-129 (2015).
41. Nikolaeva, D., Draper, S. J. & Biswas, S. Toward the development of effective transmission-blocking vaccines for malaria. Expert Rev. Vaccines 14, 653-680 (2015).
42. Li, Y. et al. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology. Sci. Rep. in press, SREP-15-24347A, (2015).
43. Kokhaei, P. et al. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp. Hematol. 35, 297-304 (2007).
44. Gedeon, P. C., Choi, B. D., Sampson, J. H. & Bigner, D. D. Rindopepimut. Drugs Future 38, 147 (2013).
45. Freivalds, J. et al. Yeast-expressed bacteriophage-like particles for the packaging of nanomaterials. Mol. Biotechnol. 56, 102-110 (2014).
46. Mbow, M. L., De Gregorio, E., Valiante, N. M. & Rappuoli, R. New adjuvants for human vaccines. Curr. Opin. Immunol. 22, 411-416 (2010).
47. Liu, Z. et al. A novel method for synthetic vaccine construction based on protein assembly. Sci. Rep. 4, 7266 (2014).
48. Bedbrook, C. N. et al. Genetically Encoded Spy Peptide Fusion System to Detect Plasma Membrane-Localized Proteins In Vivo. Chem. Biol. 22, 1108-1121 (2015).
49. Chen, A. Y. et al. Synthesis and patterning of tunable multiscale materials with engineered cells. Nat. Mater. 13, 515-523 (2014).
50. Botyanszki, Z., Tay, P. K. R., Nguyen, P. Q., Nussbaumer, M. G. & Joshi, N. S. Engineered catalytic biofilms: Site-specific enzyme immobilization onto E. coli curli nanofibers. Biotechnol. Bioeng. 112, 2016-2024 (2015).
51. Sun, F., Zhang, W.-B., Mahdavi, A., Arnold, F. H. & Tirrell, D. A. Synthesis of bioactive protein hydrogels by genetically encoded SpyTag-SpyCatcher chemistry. Proc. Natl. Acad. Sci. 111, 11269-11274 (2014).
52. Douglas, A. D. et al. A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys. Cell Host Microbe 17, 130-139 (2015).
53. Rampling, T. et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine-Preliminary Report. N. Engl. J. Med. doi: 10. 1056/ NEJMoa1411627 (2015).
54. RTS, S. Clinical Trials Partnership et al. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284-2295 (2012).
55. Kapulu, M. C. et al. Comparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum. Sci. Rep. 5, 11193 (2015).
56. Wright, K. E. et al. Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. Nature 515, 427-430 (2014).
57. RTS, S. Clinical Trials Partnership. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31-45 (2015).
58. Zakeri, B. & Howarth, M. Spontaneous Intermolecular Amide Bond Formation between Side Chains for Irreversible Peptide Targeting. J. Am. Chem. Soc. 132, 4526-4527 (2010).
59. Kang, H. J. & Baker, E. N. Intramolecular isopeptide bonds: Protein crosslinks built for stress? Trends Biochem. Sci. 36, 229-237 (2011).
60. Jennings, G. T. & Bachmann, M. F. Immunodrugs: Therapeutic VLP-based vaccines for chronic diseases. Annu. Rev. Pharmacol. Toxicol. 49, 303-326 (2009).
61. Delamarre, L., Mellman, I. & Yadav, M. Neo approaches to cancer vaccines. Science 348, 760-761 (2015).
62. Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343-345 (2009).
63. Goodman, A. L. et al. A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmissionblocking activity. PloS One 6, e29428 (2011).
64. Pardon, E., Steyaert, J. & Wyns, L. Epitope Tag for Affinity-Based Applications. EU Patent Application EP2576609 filed 01 Dec. 2011.
65. Nguyen, V. D. et al. Pre-expression of a sulfhydryl oxidase significantly increases the yields of eukaryotic disulfide bond containing proteins expressed in the cytoplasm of E. coli. Microb. Cell Factories 10, 1 (2011).
66. Cabrita, L. D. et al. Enhancing the stability and solubility of TEV protease using in silico design. Protein Sci. 16, 2360-2367 (2007).
67. Miroux, B. & Walker, J. E. Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J. Mol. Biol. 260, 289-298 (1996).
68. Zimmerman, T. et al. Simultaneous metal chelate affinity purification and endotoxin clearance of recombinant antibody fragments. J. Immunol. Methods 314, 67-73 (2006).
69. Mamat, U. et al. Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins. Microb. Cell Factories 14, 57 (2015).
70. Miura, K. et al. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26, 193-200 (2008).
71. Wu, Y. et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc. Natl. Acad. Sci. 103, 18243-18248 (2006).
72. Barr, P. J. et al. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J. Exp. Med. 174, 1203-1208 (1991)